Telocinobufagin inhibits the epithelial‑mesenchymal transition of breast cancer cells through the phosphoinositide 3‑kinase/protein
kinase B/extracellular signal‑regulated kinase/Snail signaling pathway Corrigendum in /10.3892/ol.2021.12503

Gao,Yuxue; Shi,Lihong; Cao,Zhen; Zhu,Xuetao; Li,Feng; Wang,Ruyan; Xu,Jinyuan; Zhong,Jinyi; Zhang,Baogang; Lu,Shijun

doi:10.3892/ol.2018.8349

Telocinobufagin inhibits the epithelial‑mesenchymal transition of breast cancer cells through the phosphoinositide 3‑kinase/protein kinase B/extracellular signal‑regulated kinase/Snail signaling pathway

Corrigendum in: /10.3892/ol.2021.12503

Authors:
- Yuxue Gao
- Lihong Shi
- Zhen Cao
- Xuetao Zhu
- Feng Li
- Ruyan Wang
- Jinyuan Xu
- Jinyi Zhong
- Baogang Zhang
- Shijun Lu
View Affiliations

Affiliations: Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 261053, P.R. China, Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Department of Pathology, Key Clinical Specialty for Pathology of Shandong Province, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261053, P.R. China
Published online on: March 26, 2018 https://doi.org/10.3892/ol.2018.8349
Pages: 7837-7845
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Telocinobufagin (TBG), an active ingredient of Venenumbufonis, exhibits an immunomodulatory activity. However, its antimetastatic activity in breast cancer remains unknown. The present study investigated whether TBG prevents breast cancer metastasis and evaluated its regulatory mechanism. TBG inhibited the migration and invasion of 4T1 breast cancer cells. Furthermore, TBG triggered the collapse of F‑actin filaments in breast cancer. The epithelial‑mesenchymal transition (EMT) markers, vimentin and fibronectin, were downregulated following TBG treatment. However, E‑cadherin was upregulated following TBG treatment. Snail, a crucial transcriptional factor of EMT, was downregulated following TBG treatment. Signaling pathway markers, including phosphorylated protein kinase B (P‑Akt), p‑mechanistic target of rapamycin (mTOR) and p‑extracellular signal‑regulated kinase (ERK), were decreased following TBG treatment. The same results were obtained from in vivo experiments. In conclusion, in vitro and in vivo experiments reveal that TBG inhibited migration, invasion and EMT via the phosphoinositide 3‑kinase (PI3K)/Akt/ERK/Snail signaling pathway in breast cancer.

View Figures

View References

1	Downs-Holmes C and Silverman P: Breast cancer: Overview & updates. Nurse Pract. 36:20–26. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Mehlen P and Puisieux A: Metastasis: A question of life or death. Nat Rev Cancer. 6:449–458. 2006. View Article : Google Scholar : PubMed/NCBI
4	Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, et al: Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. J Clin Oncol. 32:3848–3857. 2014. View Article : Google Scholar : PubMed/NCBI
5	Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet. 386:1341–1352. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lin H, Jie L and Ying Z: Developments in cancer prevention and treatment using traditional Chinese medicine. Front Med. 5:127–133. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W and Li X: Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res. 63:4037–4043. 2003.PubMed/NCBI
8	Chen Z and Li Y and Li Y: Review of study on mechanism of traditional Chinese medicine in treating autoimmunity disease. Zhong Yao Cai. 26:218–221. 2003.PubMed/NCBI
9	Wen MC, Wei CH, Hu ZQ, Srivastava K, Ko J, Xi ST, Mu DZ, Du JB, Li GH, Wallenstein S, et al: Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 116:517–524. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ernst E: Complementary AIDS therapies: The good, the bad and the ugly. Int J STD AIDS. 8:281–285. 1997. View Article : Google Scholar : PubMed/NCBI
11	Chan WY, Ng TB and Yeung HW: Examination for toxicity of a Chinese drug, the toad glandular secretory product chan su, in pregnant mice and embryos. Biol Neonate. 67:376–380. 1995. View Article : Google Scholar : PubMed/NCBI
12	Wu SC, Fu BD, Shen HQ, Yi PF, Zhang LY, Lv S, Guo X, Xia F, Wu YL and Wei XB: Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Int Immunopharmacol. 25:353–362. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cao Y, Song Y, An N, Zeng S, Wang D, Yu L, Zhu T, Zhang T, Cui J, Zhou C and Deng X: The effects of telocinobufagin isolated from Chan Su on the activation and cytokine secretion of immunocytes in vitro. Fundam Clin Pharmacol. 23:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
14	Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M and Tang W: Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans cantor. Int Immunopharmacol. 11:342–349. 2011. View Article : Google Scholar : PubMed/NCBI
15	Zhou LX and Guo JM: Research progress in targeted therapy for hepatocellular carcinoma. J Oncol. 15:156–161. 2009.(In Chinese).
16	Baum B, Settleman J and Quinlan MP: Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol. 19:294–308. 2008. View Article : Google Scholar : PubMed/NCBI
17	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tomaskovic-Crook E, Thompson EW and Thiery JP: Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res. 11:2132009. View Article : Google Scholar : PubMed/NCBI
19	Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
20	Mezencev R, Matyunina LV, Jabbari N and McDonald JF: Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: Systems analysis of molecular changes and their effect on radiation and drug sensitivity. BMC Cancer. 16:2362016. View Article : Google Scholar : PubMed/NCBI
21	Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002. View Article : Google Scholar : PubMed/NCBI
22	Zhang YQ, Wei XL, Liang YK, Chen WL, Zhang F, Bai JW, Qiu SQ, Du CW, Huang WH and Zhang GJ: Over-expressed twist associates with markers of epithelial mesenchymal transition and predicts poor prognosis in breast cancers via ERK and Akt activation. PLoS One. 10:e01358512015. View Article : Google Scholar : PubMed/NCBI
23	Teschendorff AE, Journee M, Absil PA, Sepulchre R and Caldas C: Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol. 3:e1612007. View Article : Google Scholar : PubMed/NCBI
24	Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, et al: Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 65:10801–10809. 2005. View Article : Google Scholar : PubMed/NCBI
25	Fedele M, Cerchia L and Chiappetta G: The epithelial-to-mesenchymal transition in breast cancer: Focus on basal-like carcinomas. Cancers (Basel). 9:pii: E134. 2017. View Article : Google Scholar : PubMed/NCBI
26	Lu S, Niu N, Guo H, Tang J, Guo W, Liu Z, Shi L, Sun T, Zhou F, Li H, et al: ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome. Eur J Cancer. 49:752–763. 2013. View Article : Google Scholar : PubMed/NCBI
27	Pardo R, Andreolotti AG, Ramos B, Picatoste F and Claro E: Opposed effects of lithium on the MEK-ERK pathway in neural cells: Inhibition in astrocytes and stimulation in neurons by GSK3 independent mechanisms. J Neurochem. 87:417–426. 2003. View Article : Google Scholar : PubMed/NCBI
28	Noritake J, Watanabe T, Sato K, Wang S and Kaibuchi K: IQGAP1: A key regulator of adhesion and migration. J Cell Sci. 118:2085–2092. 2005. View Article : Google Scholar : PubMed/NCBI
29	Jiang Y, Leung AW, Wang X, Zhang H and Xu C: Effect of photodynamic therapy with hypocrellin B on apoptosis, adhesion, and migration of cancer cells. Int J Radiat Biol. 90:575–579. 2014. View Article : Google Scholar : PubMed/NCBI
30	Yilmaz M and Christofori G: EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
31	Wu Y and Zhou BP: Epithelial-mesenchymal transition in development and diseases. Springer; New York: pp. 187–211. 2010
32	de Herreros AG, Peiró S, Nassour M and Savagner P: Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia. 15:135–147. 2010. View Article : Google Scholar : PubMed/NCBI
33	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
34	Xue G and Hemmings BA: PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst. 105:393–404. 2013. View Article : Google Scholar : PubMed/NCBI
35	Krepischi AC, Maschietto M, Ferreira EN, Silva AG, Costa SS, da Cunha IW, Barros BDF, Grundy PE, Rosenberg C and Carraro DM: Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors. Mol Cytogenet. 9:202016. View Article : Google Scholar : PubMed/NCBI
36	Zhou Q, Chen J, Feng J, Xu Y, Zheng W and Wang J: SOSTDC1 inhibits follicular thyroid cancer cell proliferation, migration, and EMT via suppressing PI3K/Akt and MAPK/Erk signaling pathways. Mol Cell Biochem. 435:87–95. 2017. View Article : Google Scholar : PubMed/NCBI
37	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
38	Shi L, Sun X, Zhang J, Zhao C, Li H, Liu Z, Fang C, Wang X, Zhao C, Zhang X, et al: Gab2 expression in glioma and its implications for tumor invasion. Acta Oncol. 52:1739–1750. 2013. View Article : Google Scholar : PubMed/NCBI
39	Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and De Herreros García A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
40	Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
41	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI